Page last updated: 2024-12-08

licam-c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

LICAM-C: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID173493
MeSH IDM0107108

Synonyms (8)

Synonym
licam-c
4-[4-[(4-carboxy-2,3-dihydroxybenzoyl)-[3-[(4-carboxy-2,3-dihydroxybenzoyl)amino]propyl]amino]butylcarbamoyl]-2,3-dihydroxybenzoic acid
benzoic acid, 4-(((4-((4-carboxy-2,3-dihydroxybenzoyl)amino)butyl)(3-((4-carboxy-2,3-dihydroxybenzoyl)amino)propyl)amino)carbonyl)-2,3-dihydroxy-
n,n',n''-tris(2,3-dihydroxy-4-carboxybenzoyl)-1,5,10-triazadecane
75956-68-2
DTXSID90226858
4-((4-(4-carboxy-2,3-dihydroxybenzamido)butyl)(3-(4-carboxy-2,3-dihydroxybenzamido)propyl)carbamoyl)-2,3-dihydroxybenzoic acid
AKOS040752563

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" With early treatment and at the dosage used clinically for the decorporation of actinides with DTPA (30 mumol/kg body weight) LICAM(C) was superior to DFOA but when compared with DTPA, the effect of LICAM(C) on 238Pu was greater only in bone; as little as 1 mumol LICAM(C)/kg was as effective as 30 mumol DTPA/kg."( Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFOA in rats, hamsters and mice.
Volf, V, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (94.44)18.7374
1990's1 (5.56)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]